نتایج جستجو برای: paronychia lordeganica
تعداد نتایج: 220 فیلتر نتایج به سال:
Dacomitinib is a second-generation, irreversible, covalent pan-HER tyrosine-kinase inhibitor (TKI). It showed potent EGFR signaling inhibition in experimental models, including first-generation TKI-resistant non-small cell lung cancer (NSCLC) cell lines. This preclinical efficacy did not translate into clinically meaningful treatment benefits for advanced, pretreated, molecularly unselected NSC...
First-line therapy with an EGFR tyrosine kinase inhibitor (TKI) is standard of care for patients EGFR-mutated NSCLC. Whereas osimertinib sensitive to the acquired mutation T790M in 1st/2nd generation EGFR-TKI resistant patient, afatinib overcomes resistance due highly express HER2/HER3 or C797S mutations. Osimertinib and may deliver drug efficacy a complement manner, therefore, we conducted pha...
BACKGROUND Chemotherapy is standard neoadjuvant treatment of LA BC. Patients with HER2-positive BC require targeted therapy. Trastuzumab and pertuzumab, which target HER2, with chemotherapy are approved as neoadjuvant therapy, however, treatments with different mechanisms of action might provide a broader range of activity. In this study we evaluated the efficacy and safety of the irreversible ...
OBJECTIVE In Japan, cisplatin/5-fluorouracil 80/800 (cisplatin 80 mg/m2, 5-fluorouracil 800 mg/m2) is widely used to treat recurrent/metastatic squamous cell carcinoma of the head and neck, whereas cisplatin/5-fluorouracil 100/1000 (1000 mg/m2/24 h by continuous intravenous infusion on Days 1-4 plus cisplatin 100 mg/m2 on Day 1 in 3-week cycles) is the standard treatment in Europe and North Ame...
In discussions of eczema, brief mention is usually made of the fact that superimposed infection often complicates the disease, but one does not gather that the secondary malady is regarded as a factor which may be of prime importance in determining the clinical pattern of the sickness. The parasites may be viruses, fungi, or bacteria and the infection may be single or multiple in etiology. Exam...
612 EJD, vol. 21, n◦ 4, July-August 2011 are sporadic, although autosomal dominant inheritance and germline mosaicisms have been described. The molecular basis of the disorder is a mutation of exon IIIa in the gene coding for fibroblast growth factor receptor-2 (FGFR-2), located on chromosome 10q26. Two FGFR2 gene missense mutations involving the substitution of one of two adjacent residues, Se...
We systematically compared the adverse effects of cancer drugs to detect event outliers across different clinical trials using a data-driven approach. Because many cancer drugs are toxic to patients, better understanding of adverse events of cancer drugs is critical for developing therapies that could minimize the toxic effects. However, due to the large variabilities of adverse events across d...
OBJECTIVES To determine the safety, tolerability and signs of efficacy of MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF), in patients with rheumatoid arthritis (RA). METHODS Patients with active, moderate RA were enrolled in a randomised, multicentre, double-blind, placebo-controlled, dose-escalation trial of intravenous MOR103 (0.3, 1.0 or 1....
A healthy 2-year-old girl was referred for toenail thickening and yellow discoloration; she was otherwise asymptomatic. The patient had no history of diabetes, infection, or trauma to her toenails. Physical examination revealed both great toenails to have marked thickening of the nail plate with closely spaced transverse superficial ridging, lack of luster, and dark tanyellowish discoloration (...
PURPOSE Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone (HR)–positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances single blockade. The ALTERNATIVE study evaluated the efficacy and safety of dual aromatase inhibitor (AI) postmenopausal women with HER2-positive/HR-positive MBC...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید